Henry Ford Health System

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Henry Ford Health System sits in the top decile of US sponsors by registered trial count (#140 of 15,742 sponsors by registered trial count).

234 total trials 43 currently recruiting 148 completed top decile by trial count

Henry Ford Health System: 234 sponsored US clinical trials, 43 recruiting.

Henry Ford Health System sponsors 234 registered US clinical trials on ClinicalTrials.gov, 43 of them currently recruiting, and 148 completed. 35 of these trials are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Insomnia, with 5 trials.

Top-decile sponsor footprint

Henry Ford Health System ranks in the top decile of sponsors by registered trial count (#140 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 53/100

148 of 173 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

234 total, page 2 of 5

ACTIVE NOT RECRUITING Phase 2

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

NCT05478551

ACTIVE NOT RECRUITING NA

Anterior Cruciate Ligament Reconstruction Hybrid Remnant Repair

NCT05494073

ACTIVE NOT RECRUITING NA

Optimizing Phototesting and Investigating Photobiology of Visible Light

NCT05964907

ACTIVE NOT RECRUITING

Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia

NCT05296590

ACTIVE NOT RECRUITING Phase 2

Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects

NCT04181476

ACTIVE NOT RECRUITING

Assessment of Breast Cancer Patients Satisfaction and Health Related Quality of Life Outcomes

NCT03333122

NOT YET RECRUITING NA

Maneuvers to Reduce Laparoscopic Pain

NCT07583433

NOT YET RECRUITING NA

Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

NCT07418853

NOT YET RECRUITING NA

Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use

NCT07672808

NOT YET RECRUITING

Sleep Patterns After Total Joint Replacement Surgery

NCT04896892

NOT YET RECRUITING Phase 2

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

NCT07450183

COMPLETED NA

Peer-Delivered Episodic Future Thinking for Returning Citizens

NCT06119503

COMPLETED NA

Train Your Brain: A Pilot Project to Improve Memory and Decision Making

NCT05879198

COMPLETED NA

Engaging Patients for Physical Exams During Virtual Care Visits

NCT05790811

COMPLETED NA

Reducing Alcohol Use Post-Bariatric Surgery

NCT04788316

COMPLETED NA

Preventing Insomnia With Virtual Oneshot Therapy (PIVOT)

NCT05523726

COMPLETED Phase 4

Intermittent Bolus vs Continuous Infusion Via ESP Catheters RCT

NCT05642416

COMPLETED NA

Telemedicine Mindfulness-based Therapy for Perinatal Insomnia: An Open-label Trial.

NCT04443959

COMPLETED NA

Feasibility of Semi-Permanent Tattoo for Treatment Alignment in Radiation Therapy

NCT05248009

COMPLETED NA

Improving Future Thinking Among Mothers to Reduce Harsh Parenting and Improve Child Outcomes

NCT05229146

COMPLETED NA

Use of Consumer Sleep Technology to Treat Shift Work Disorder

NCT05186233

COMPLETED NA

Improving Delay Discounting to Decrease Harsh Parenting Among Parents Receiving Substance Use Treatment

NCT05229120

COMPLETED NA

FOREward Together: Training Peer Recovery Coaches to Promote Retention and Adherence to MOUD

NCT05098795

COMPLETED NA

Comparison of Intraoperative HR and RR Acquired Via ATLASense Raphael PolyMonitor and Standard Intraoperative Monitors

NCT05291949

COMPLETED NA

Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance

NCT05138328

COMPLETED

Pressure-Volume Loop During High-Risk PCI

NCT04681313

COMPLETED

Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients

NCT04723706

COMPLETED NA

Improving Negative Stressful Perseverations in Insomnia to Revitalize Expectant Moms

NCT04445805

COMPLETED

Toward High Fidelity Adaptive Radiotherapy in the Thorax

NCT04731571

COMPLETED Phase 4

Safety of Gebauer's Pain Ease and Gebauer's Ethyl Chloride

NCT04207710

COMPLETED NA

Reduce Emotional Symptoms of Insomnia With SleepTreatment

NCT03724305

COMPLETED NA

Use of Blood Flow Restriction (BFR) Therapy in Post-operative Rehabilitation Following Distal Biceps Tendon Repair

NCT04503421

COMPLETED

SARS-CoV-2 IgG and IgM Serologic Assays

NCT04562246

COMPLETED NA

Pre-visit Digital Messaging Improves Patient Reported Outcome Measure Participation Prior to the Orthopedic Ambulatory Visit

NCT04983641

COMPLETED NA

Rapid Acute Coronary Syndrome Exclusion Using High-sensitivity I Troponin

NCT04488913

COMPLETED NA

Use of Blood Flow Restriction Therapy Following ACL Tear

NCT04374968

COMPLETED NA

Conduction Disease After Transcatheter Aortic Valve Replacement

NCT04489095

TERMINATED

Cooled Versus Conventional Genicular Radiofrequency Ablation for Chronic Knee Pain

NCT04275128

COMPLETED

The Effect of Midazolam Sedation on Diagnostic Medial Branch Blocks

NCT04453449

COMPLETED

Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays

NCT04562285

TERMINATED NA

BFR Therapy in Patients With Rotator Cuff Tears

NCT04384120

COMPLETED Phase 2

Convalescent Plasma for Patients With COVID-19

NCT04385199

TERMINATED Phase 3

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441

COMPLETED

Early Short Course Corticosteroids in COVID-19

NCT04374071

TERMINATED Phase 2

Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma

NCT04743999

COMPLETED

Novel Decision Aid for Carpal Tunnel Patients

NCT04693273

TERMINATED NA

Well-arm Exercise in Distal Radius Fractures

NCT04089709

COMPLETED NA

Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa

NCT05927948

TERMINATED Phase 4

Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT04148105

COMPLETED Early Phase 1

HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

NCT04188951

← Previous Page 2 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 23
Phase 3 9
Phase 4 26

What is open in the Henry Ford Health System pipeline

43 recruiting of 234 indexed (18% open); 148 completed (63%).

Phase mix: 35 late (III/IV) vs 38 early (I/II) (balanced across stages).

Top condition: Insomnia (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Henry Ford Health System: open-pipeline peers nationwide

Peers matched on 234 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Henry Ford Health System sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 10%12%14%16%18%20% Total trials Recruiting share Henry Ford Health SystemDaiichi SankyoLoma Linda UniversityBrown UniversityUniversity Hospitals Cleveland Medical CenterNew York Institute of TechnologyUniversity of Maryland, BaltimoreAbramson Cancer Center at Penn MedicineUniversity of California, San Diego
Henry Ford Health System sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Henry Ford Health System sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 234 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Henry Ford Health System page

234 registered trials is a research-attention snapshot, not an endorsement of Henry Ford Health System or any single study.

  • 43 of Henry Ford Health System's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Insomnia is the condition Henry Ford Health System studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Insomnia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Henry Ford Health System pipeline card: 234 registered trials from official public datasets.Report a data error.